Evaluation of Clinical Response to Neoadjuvant Chemoradiotherapy and its Comparison with Postoperative Pathologic Response in Patients with Esophageal Cancer in “5th December” Hospital in Gorgan

• Main Authors: Ali Arian Nia, Farzaneh Gholizadeh, Mahdi Babaei Hatkehlouei, Reza Khandoozi
• Format: Article
• Language: English
• Published: Amber Publication 2018-01-01
• Series: Journal of Research in Medical and Dental Science
• Subjects: Esophageal Cancer; Neoadjuvant Chemoradiotherapy; Pathologic Response; Gorgan
• Online Access: https://www.jrmds.in/articles/evaluation-of-clinical-response-to-neoadjuvant-chemoradiotherapy-and-its-comparison-with-postoperative-pathologic-respon.pdf

Esophageal cancer is an invasive disease, and various treatments have been proposed to improve the survival of patients with it. In this study, the results of clinical response to neoadjuvant chemoradiotherapy in patients were evaluated and then these results were compared with the postoperative pathological responses. This crosssectional and descriptive-analytic study was performed on 60 resection able esophageal cancer patients who were referred to educational hospitals from April 2011 to 2017. The response to treatment of these patients before and after neoadjuvant chemoradiotherapy was evaluated using CT and EUS and compared with pathologic changes after surgery. Of the 60 patients who underwent endosonography and CT scan before neoadjuvant, 11 patients were at stage A2 (18.3%), 13 at stage B2 (21.7%), 15 at stage A3 (25%), 11 at stage B3 (18.3% ), and 10 at stage C3 (16.7%). After neo-adjuvant surgery and pathology-based surgery, 24 (40%) responded fully to treatment. 32 patients (53.3%) had partial response and stage decrease, following 9 at stage 1 (4 stage A1, 5 stage B1), 19 at stage 2 (10 at stage A2, 9 at stage B2), 4 at stage 3 (2 at stage A3, 2 at stage B3), and 4 patients (6.6%) did not have any changes in the stage of the disease and did not respond to treatment. In this study, from patients undergoing chemoradiotherapy, 40% received complete pathologic response to treatment with satisfactory results and acceptable complications, and further consideration and evaluation is recommended in this regard.